KR20230154793A - 암 치료를 위한 병용 요법 - Google Patents

암 치료를 위한 병용 요법 Download PDF

Info

Publication number
KR20230154793A
KR20230154793A KR1020237023446A KR20237023446A KR20230154793A KR 20230154793 A KR20230154793 A KR 20230154793A KR 1020237023446 A KR1020237023446 A KR 1020237023446A KR 20237023446 A KR20237023446 A KR 20237023446A KR 20230154793 A KR20230154793 A KR 20230154793A
Authority
KR
South Korea
Prior art keywords
compound
formula
egfr
cancer
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020237023446A
Other languages
English (en)
Korean (ko)
Inventor
리누스 마틴
레슬리 해리스 브레일
로버트 필드 슈메이커
Original Assignee
에라스카, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에라스카, 아이엔씨. filed Critical 에라스카, 아이엔씨.
Publication of KR20230154793A publication Critical patent/KR20230154793A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020237023446A 2020-12-11 2021-12-10 암 치료를 위한 병용 요법 Abandoned KR20230154793A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063124665P 2020-12-11 2020-12-11
US63/124,665 2020-12-11
US202163214718P 2021-06-24 2021-06-24
US63/214,718 2021-06-24
US202163253012P 2021-10-06 2021-10-06
US63/253,012 2021-10-06
US202163277561P 2021-11-09 2021-11-09
US63/277,561 2021-11-09
PCT/US2021/062912 WO2022125962A1 (en) 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20230154793A true KR20230154793A (ko) 2023-11-09

Family

ID=81974006

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237023446A Abandoned KR20230154793A (ko) 2020-12-11 2021-12-10 암 치료를 위한 병용 요법

Country Status (7)

Country Link
US (1) US20240050441A1 (enExample)
EP (1) EP4259147A4 (enExample)
JP (1) JP2023553532A (enExample)
KR (1) KR20230154793A (enExample)
AU (1) AU2021396395A1 (enExample)
CA (1) CA3201657A1 (enExample)
WO (1) WO2022125962A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
US20240102099A1 (en) * 2020-11-20 2024-03-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and compositions relating to a novel epidermal growth factor receptor (egfr) splice variant
US20250195533A1 (en) * 2020-12-11 2025-06-19 Erasca, Inc. Combination therapies for the treatment of cancer
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
TW202322809A (zh) * 2021-10-06 2023-06-16 美商艾瑞斯卡公司 三取代雜芳基衍生物作為src同源-2磷酸酶抑制劑之用途
WO2025226830A1 (en) * 2024-04-23 2025-10-30 Erasca, Inc. Shp2 and egfr inhibitors for the treatment of chordoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188802A1 (en) * 2008-03-06 2013-04-30 Genentech Inc Combination therapy with c-met and egfr antagonists
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
JP2016503399A (ja) * 2012-10-25 2016-02-04 ノバルティス アーゲー 組合せ
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
JP7337174B2 (ja) * 2018-09-18 2023-09-01 ニカング セラピューティクス， インコーポレイテッド Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
JP2022526159A (ja) * 2019-03-29 2022-05-23 アストラゼネカ・アクチエボラーグ 非小細胞肺がんの治療に使用するためのオシメルチニブ
CA3164995A1 (en) * 2019-12-20 2021-06-24 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2021173923A1 (en) * 2020-02-28 2021-09-02 Erasca, Inc. Pyrrolidine-fused heterocycles

Also Published As

Publication number Publication date
US20240050441A1 (en) 2024-02-15
EP4259147A1 (en) 2023-10-18
JP2023553532A (ja) 2023-12-21
CA3201657A1 (en) 2022-06-16
EP4259147A4 (en) 2024-10-23
WO2022125962A1 (en) 2022-06-16
AU2021396395A1 (en) 2023-07-27
AU2021396395A9 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
US20240293422A1 (en) Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
US20190062444A1 (en) Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US11583577B2 (en) Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
US20240050441A1 (en) Combination therapies for the treatment of cancer
KR20230151981A (ko) 암 치료를 위한 병용 요법
KR20230152652A (ko) 암 치료를 위한 병용 요법
JP2019511554A (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
CN117098537A (zh) 用于癌症治疗的联合疗法
TW202409075A (zh) 用莫蘇妥珠單抗及來那度胺治療先前未經治療的濾泡性淋巴瘤之方法
HK40103380A (en) Combination therapies for the treatment of cancer
US20240285624A1 (en) Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
CN117120449A (zh) 用于癌症治疗的联合疗法
CN117083283A (zh) 用于癌症治疗的联合疗法
HK40103172A (en) Combination therapies for the treatment of cancer
HK40103377A (zh) 用於癌症治疗的联合疗法
WO2025226830A1 (en) Shp2 and egfr inhibitors for the treatment of chordoma
WO2023059771A1 (en) Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
TW202011991A (zh) 用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1902 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1902 Submission of document of abandonment before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1902